HIV-1 Antagonism of CD317 Is Species Specific and Involves Vpu-Mediated Proteasomal Degradation of the Restriction Factor

Cell Host and Microbe

Volumn 5, Issue 3, 2009, Pages 285-297

  Goffinet, Christine ^a   Allespach, Ina ^a   Homann, Stefanie ^a   Tervo, Hanna Mari ^a   Habermann, Anja ^a   Rupp, Daniel ^a   Oberbremer, Lena ^a   Kern, Christian ^a   Tibroni, Nadine ^a   Welsch, Sonja ^a,b,c   Krijnse Locker, Jacomine ^a,b   Banting, George ^d   Kräusslich, Hans Georg ^a   Fackler, Oliver T ^a   Keppler, Oliver T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

MICROBIO; MOLIMMUNO

Indexed keywords

CD317 ANTIGEN; MEMBRANE PROTEIN; PROTEASOME; UNCLASSIFIED DRUG; VPU PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SPECIES DIFFERENCE; VIRION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS PARTICLE;

ANIMALS; ANTIGENS, CD; CELL LINE; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; RATS; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRULENCE FACTORS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA; RATTUS; RODENTIA;

EID: 61849183569     PISSN: 19313128     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chom.2009.01.009     Document Type: Article

References (47)

1. Bartee E., McCormack A., and Früh K. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2 (2006) e107
2. Bieniasz P.D. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5 (2004) 1109-1115
3. Blasius A.L., Giurisato E., Cella M., Schreiber R.D., Shaw A.S., and Colonna M. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J. Immunol. 177 (2006) 3260-3265
4. Bour S., Schubert U., Peden K., and Strebel K. The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?. J. Virol. 70 (1996) 820-829
5. Bour S.P., Aberham C., Perrin C., and Strebel K. Lack of effect of cytoplasmic tail truncations on human immunodeficiency virus type 2 ROD env particle release activity. J. Virol. 73 (1999) 778-782
6. Browne E.P., and Littman D.R. Species-specific restriction of apobec3-mediated hypermutation. J. Virol. 82 (2008) 1305-1313
7. Chiu Y.L., and Greene W.C. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26 (2008) 317-353
8. Fackler O.T., Moris A., Tibroni N., Giese S.I., Glass B., Schwartz O., and Kräusslich H.G. Functional characterization of HIV-1 Nef mutants in the context of viral infection. Virology 351 (2006) 322-339
9. Fenteany G., Standaert R.F., Lane W.S., Choi S., Corey E.J., and Schreiber S.L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268 (1995) 726-731
10. Geuenich S., Goffinet C., Venzke S., Nolkemper S., Baumann I., Plinkert P., Reichling J., and Keppler O.T. Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density. Retrovirology 5 (2008) 27
11. Goff S.P. Retrovirus restriction factors. Mol. Cell 16 (2004) 849-859
12. Goila-Gaur R., and Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5 (2008) 51
13. Goto T., Kennel S.J., Abe M., Takishita M., Kosaka M., Solomon A., and Saito S. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 84 (1994) 1922-1930
14. Göttlinger H.G., Dorfman T., Cohen E.A., and Haseltine W.A. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc. Natl. Acad. Sci. USA 90 (1993) 7381-7385
15. Hannemann S., Madrid R., Stastna J., Kitzing T., Gasteier J., Schönichen A., Bouchet J., Jimenez A., Geyer M., Grosse R., et al. The Diaphanous-related Formin FHOD1 associates with ROCK1 and promotes Src-dependent plasma membrane blebbing. J. Biol. Chem. 283 (2008) 27891-27903
16. Iida S., Fukumori T., Oshima Y., Akari H., Koyama A.H., and Adachi A. Compatibility of Vpu-like activity in the four groups of primate immunodeficiency viruses. Virus Genes 18 (1999) 183-187
17. Ishikawa J., Kaisho T., Tomizawa H., Lee B.O., Kobune Y., Inazawa J., Oritani K., Itoh M., Ochi T., Ishihara K., et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 26 (1995) 527-534
18. Keppler O.T., Welte F.J., Ngo T.A., Chin P.S., Patton K.S., Tsou C.L., Abbey N.W., Sharkey M.E., Grant R.M., You Y., et al. Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J. Exp. Med. 195 (2002) 719-736
19. Keppler O.T., Allespach I., Schüller L., Fenard D., Greene W.C., and Fackler O.T. Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef. J. Virol. 79 (2005) 1655-1665
20. Klimkait T., Strebel K., Hoggan M.D., Martin M.A., and Orenstein J.M. The human immunodeficiency virus type 1-specific protein Vpu is required for efficient virus maturation and release. J. Virol. 64 (1990) 621-629
21. Kupzig S., Korolchuk V., Rollason R., Sugden A., Wilde A., and Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4 (2003) 694-709
22. Malim M.H., and Emerman M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3 (2008) 388-398
23. Mariani R., Chen D., Schröfelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., and Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114 (2003) 21-31
24. Neil S.J., Eastman S.W., Jouvenet N., and Bieniasz P.D. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog. 2 (2006) e39
25. Neil S.J., Sandrin V., Sundquist W.I., and Bieniasz P.D. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2 (2007) 193-203
26. Neil S.J., Zang T., and Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451 (2008) 425-430
27. Nguyen K.L., Llano M., Akari H., Miyagi E., Poeschla E.M., Strebel K., and Bour S. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 319 (2004) 163-175
28. Noble B., Abada P., Nunez-Iglesias J., and Cannon P.M. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J. Virol. 80 (2006) 2924-2932
29. Pfeiffer T., Pisch T., Devitt G., Holtkotte D., and Bosch V. Effects of signal peptide exchange on HIV-1 glycoprotein expression and viral infectivity in mammalian cells. FEBS Lett. 580 (2006) 3775-3778
30. Ritter Jr. G.D., Yamshchikov G., Cohen S.J., and Mulligan M.J. Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain. J. Virol. 70 (1996) 2669-2673
31. Sakuma R., Noser J.A., Ohmine S., and Ikeda Y. Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nat. Med. 13 (2007) 631-635
32. Schubert U., Henklein P., Boldyreff B., Wingender E., Strebel K., and Porstmann T. The human immunodeficiency virus type 1 encoded Vpu protein is phosphorylated by casein kinase-2 (CK-2) at positions Ser52 and Ser56 within a predicted alpha-helix-turn-alpha-helix-motif. J. Mol. Biol. 236 (1994) 16-25
33. Schubert U., Clouse K.A., and Strebel K. Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J. Virol. 69 (1995) 7699-7711
34. Schubert U., Bour S., Willey R.L., and Strebel K. Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env. J. Virol. 73 (1999) 887-896
35. Schubert U., Ott D.E., Chertova E.N., Welker R., Tessmer U., Princiotta M.F., Bennink J.R., Kräusslich H.G., and Yewdell J.W. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc. Natl. Acad. Sci. USA 97 (2000) 13057-13062
36. Sebastian S., and Luban J. The Retroviral Restriction Factor TRIM5alpha. Curr. Infect. Dis. Rep. 9 (2007) 167-173
37. Simon J.H., Gaddis N.C., Fouchier R.A., and Malim M.H. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4 (1998) 1397-1400
38. Stopak K., de Noronha C., Yonemoto W., and Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12 (2003) 591-601
39. Strebel K. HIV accessory genes Vif and Vpu. Adv. Pharmacol. 55 (2007) 199-232
40. Towers G.J. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 4 (2007) 40
41. Uchil P.D., Quinlan B.D., Chan W.T., Luna J.M., and Mothes W. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog. 4 (2008) e16
42. Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., and Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3 (2008) 245-252
43. Vartanian J.P., Guetard D., Henry M., and Wain-Hobson S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320 (2008) 230-233
44. Varthakavi V., Smith R.M., Bour S.P., Strebel K., and Spearman P. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc. Natl. Acad. Sci. USA 100 (2003) 15154-15159
45. Varthakavi V., Smith R.M., Martin K.L., Derdowski A., Lapierre L.A., Goldenring J.R., and Spearman P. The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 7 (2006) 298-307
46. Varthakavi V., Heimann-Nichols E., Smith R.M., Sun Y., Bram R.J., Ali S., Rose J., Ding L., and Spearman P. Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu. Nat. Med. 14 (2008) 641-647
47. Wolf D., and Goff S.P. TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells. Cell 131 (2007) 46-57